Recent advances in the development of immunostimulatory oligonucleotides (original) (raw)
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists
jimmy tang
Proceedings of the National Academy of Sciences, 2005
View PDFchevron_right
A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif
jimmy tang
Proceedings of the National Academy of Sciences, 2003
View PDFchevron_right
Modifications Incorporated in CpG Motifs of Oligodeoxynucleotides Lead to Antagonist Activity of Toll-like Receptors 7 and 9
Fugang Zhu
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Development of CpG-oligodeoxynucleotides for effective activation of rabbit TLR9 mediated immune responses
Ping-hui Tseng
PloS one, 2014
View PDFchevron_right
Synthetic oligonucleotides as modulators of inflammation
Sven Klaschik
Journal of Leukocyte Biology, 2008
View PDFchevron_right
Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity
Klaus Heeg
Immunology, 2008
View PDFchevron_right
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles
jimmy tang
Nucleic Acids Research, 2003
View PDFchevron_right
Synthetic immunostimulatory oligonucleotides in experimental and clinical practice
Janusz Kocik
Pharmacological Reports, 2012
View PDFchevron_right
Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation
Paul J Payette
Immunology, 2004
View PDFchevron_right
Immune-Stimulatory Dinucleotide at the 5′-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses
Mallikarjuna Putta
ACS Medicinal Chemistry Letters, 2013
View PDFchevron_right
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities
Paul J Payette
European journal of immunology, 2004
View PDFchevron_right
Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants
Hidekazu Ikeuchi
Vaccine, 2010
View PDFchevron_right
Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction
Atie Suwarti
Biochemical and biophysical research communications, 2013
View PDFchevron_right
CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
Nobutaka Hanagata
International Journal of Nanomedicine, 2017
View PDFchevron_right
CpG-DNA as immune response modifier
Klaus Heeg
International Journal of Medical Microbiology, 2004
View PDFchevron_right
Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications
Mallikarjuna Putta
2006
View PDFchevron_right
CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses
Chiou-Hwa Cathy Yuh
Scientific reports, 2017
View PDFchevron_right
Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9
jimmy tang
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Non-CpG-Containing Antisense 2′-Methoxyethyl Oligonucleotides Activate a Proinflammatory Response Independent of Toll-Like Receptor 9 or Myeloid Differentiation Factor 88
Sebastien Burel
Journal of Pharmacology and Experimental Therapeutics, 2005
View PDFchevron_right
Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity
Arthur Krieg
Journal of Leukocyte Biology, 2004
View PDFchevron_right
CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
hira khan
Pharmaceutics, 2021
View PDFchevron_right
Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and refinement of the active motif
Juan Rodriguez
Oligonucleotides, 2006
View PDFchevron_right
The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes
Tara Roberts
Molecular Immunology, 2011
View PDFchevron_right
Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9
Ihsan Gursel
Seminars in Immunology, 2004
View PDFchevron_right
Synthetic Oligodeoxynucleotides Inhibit IgE Induction in Human Lymphocytes
Shigeharu Fujieda
American Journal of Respiratory and Critical Care Medicine, 2000
View PDFchevron_right
Toll-Like Receptor 9-Independent Suppression of Skin Inflammation by Oligonucleotides
Andor Pivarcsi
Journal of Investigative Dermatology, 2007
View PDFchevron_right
Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells
Simona Sivori
European Journal of Immunology, 2006
View PDFchevron_right
An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems
Paulo Fontoura
The Journal of Immunology, 2003
View PDFchevron_right
Therapeutic Applications and Mechanisms Underlying the Activity of Immunosuppressive Oligonucleotides
Sven Klaschik
Annals of the New York Academy of Sciences, 2009
View PDFchevron_right
Structural requirements and applications of inhibitory oligodeoxyribonucleotides
Petar Lenert
Immunologic Research, 2007
View PDFchevron_right
DEC-205 is a cell surface receptor for CpG oligonucleotides
Mireille Lahoud
2012
View PDFchevron_right
IN VIVO EFFECT OF CPG OLIGODEOXYNUCLEOTIDES (CPG ODNS) ON THE EXPRESSION OF TOLL-LIKE RECEPTOR9 (TLR9) IN CATLA CATLA
Uma Arumugam
View PDFchevron_right
Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo
Mallikarjuna Putta
Organic & Biomolecular Chemistry, 2013
View PDFchevron_right
Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides
Tara Roberts
Journal of immunology (Baltimore, Md. : 1950), 2005
View PDFchevron_right